Skip to main content

Table 6 Baseline characteristics of the CardioBBEAT study participants - Therapy

From: First outline and baseline data of a randomized, controlled multicenter trial to evaluate the health economic impact of home telemonitoring in chronic heart failure – CardioBBEAT

Characteristic All patients n = 621 Usual care n = 319 (51 %) Monitoring n = 302 (49 %) p value
Medication     
  ACE inhibitor/ARB, n (%) 577 (93) 297 (93) 280 (93) 0.974
  Beta blocker – number/total number (%) 591/620 (95) 303/319 (95) 288/301 (96) 0.826
  MR antagonist, n (%) 439 (71) 232 (73) 207 (69) 0.291
  Diuretics, n (%) 506 (82) 255 (80) 251 (83) 0.360
  Glycosides, n (%) 95 (15) 50 (16) 45 (15) 0.876
  Amiodarone, n (%) 80 (13) 48 (15) 32 (11) 0.125
  Anticoagulation, n (%)     
   Vitamin K antagonist 231 (37) 122 (38) 109 (36) 0.637
   Other 42 (7) 24 (8) 18 (6) 0.538
Devices, n (%)     
  Pacemaker 101 (16) 61 (19) 40 (13) 0.061
  ICD     0.280
   with monitoring 63 (10) 31 (10) 32 (11)  
   without monitoring 242 (39) 134 (42) 108 (36)  
  CRT-D 89 (14) 40 (13) 49 (16) 0.232
  1. ACE angiotensin converting enzyme, ARB angiotensin receptor blocker, CRT-D cardiac resynchronization therapy combined with defibrillation ICD implantable cardioverter defibrillator, MR mineralocorticoid receptor